| { | |
| "id": "07d8bf30-1ff4-463c-b4e7-09241fdfe69e", | |
| "disease": { | |
| "id": "H00056", | |
| "names": [ | |
| "Alzheimer disease", | |
| "Dementia due to Alzheimer disease" | |
| ], | |
| "dbLinks": { | |
| "icd10": [ | |
| "G30" | |
| ], | |
| "mesh": [ | |
| "D000544" | |
| ] | |
| }, | |
| "category": "Neurodegenerative disease" | |
| }, | |
| "article": { | |
| "id": "8113792", | |
| "text": "Almost all patients \u003e 40 years of age with Down's syndrome (DS) develop the pathology characteristic of Alzheimer's disease: abundant beta-amyloid plaques and neurofibrillary tangles. We have investigated the gene expression of beta-amyloid protein precursor (APP) and tau in DS and age-matched control brains and found that levels of both mRNAs were significantly elevated in DS. Such up-regulation was not observed in two other neuronal proteins. A correlation between total APP and tau mRNA levels was also found in DS brain but distinct from the pattern observed in normal brain. Although a proportionality existed between APP-695 mRNA and three-repeat tau mRNA in DS, the proportionality between APP-751 mRNA and four-repeat tau mRNA, which is normally present, was not observed. Thus, DS brains are primarily characterized by the up-regulation of tau mRNA as well as APP mRNA and disruption of the coordinate expression between APP-751 and four-repeat tau." | |
| }, | |
| "questions": [ | |
| { | |
| "id": "5e05a017-96ba-4e63-8c92-85faa233dc56", | |
| "text": "What are the risk factors of Alzheimer disease?", | |
| "answers": [ | |
| { | |
| "answer_start": 11, | |
| "text": "patients \u003e 40 years of age with Down's syndrome (DS)" | |
| } | |
| ] | |
| } | |
| ] | |
| } |